December 20, 2014 9:59 PM ET

Pharmaceuticals

Company Overview of BioSante Pharmaceuticals, Inc.

Company Overview

As of June 20, 2013, BioSante Pharmaceuticals, Inc. was acquired by ANI Pharmaceuticals, Inc., in a reverse merger transaction. BioSante Pharmaceuticals, Inc., a pharmaceutical company, focuses on the development of products for female sexual health, menopause, contraception, and male hypogonadism. It provides LibiGel, a daily transdermal testosterone gel in Phase III development for the treatment of female sexual dysfunction; Male testosterone gel, a daily transdermal testosterone gel approved by the U.S. Food and Drug Administration (FDA) for the treatment of hypogonadism or testosterone deficiency in men; The Pill-Plus, a triple component contraceptive in Phase II development; and Elestri...

111 Barclay Boulevard

Lincolnshire, IL 60069

United States

Founded in 1996

23 Employees

Phone:

847-478-0500

Fax:

847-478-9152

Key Executives for BioSante Pharmaceuticals, Inc.

BioSante Pharmaceuticals, Inc. does not have any Key Executives recorded.

BioSante Pharmaceuticals, Inc. Key Developments

BioSante Pharmaceuticals, Inc.(NasdaqGM:BPAX) dropped from NASDAQ Composite Index

BioSante Pharmaceuticals, Inc. will be removed from NASDAQ Composite Index.

Biosante Pharmaceuticals, Inc. Announces Auditor Changes

On June 19, 2013, Biosante Pharmaceuticals, Inc. dismissed Deloitte & Touche LLP as the company’s independent registered public accounting firm and appointed EisnerAmper LLP as the company’s independent registered public accounting firm for the year ending December 31, 2013.

BioSante Pharmaceuticals, Inc. Announces Management Changes

BioSante Pharmaceuticals, Inc. announced that in connection with the completion of the Merger and in accordance with the terms of the Merger Agreement, the Board of Directors of the company accepted the resignations, dated June 19, 2013, of the following directors of the company, with such resignations to be effective at completion of the Merger: Louis W. Sullivan, M.D., Stephen M. Simes, John T. Potts, Jr., M.D., Edward C. Rosenow III, M.D. and Stephen A. Sherwin, M.D. The Board of Directors also accepted the resignations, dated June 19, 2013, of the executive officers of the company, with such resignations to be effective at completion of the Merger: Stephen M. Simes as President and Chief Executive Officer and Phillip B. Donenberg as Senior Vice President of Finance, Chief Financial Officer and Secretary. The Board of Directors furthermore fixed the number of directors at seven, and elected the following five individuals to serve as directors, effective at completion of the Merger and until the company's next annual meeting of stockholders, until their respective successors are elected and qualified or until their earlier resignation or removal: Robert E. Brown, Jr., Arthur S. Przybyl, Tracy L. Marshbanks, Thomas A. Penn and Robert Schrepfer. These individuals join Fred Holubow and Ross Mangano on the Company's Board of Directors. Robert E. Brown, Jr. was appointed Chairman of the Board and the committees of the Board of Directors were reconstituted as follows, effective at completion of the Merger: Audit and Finance Committee: Tracy L. Marshbanks, Ph.D. (Chair), Robert Schrepfer and Fred Holubow. Compensation Committee: Tracy L. Marshbanks, Ph.D. (Chair), Robert Schrepfer and Ross Mangano. Nominating and Corporate Governance Committee: Robert Schrepfer (Chair), Tracy L. Marshbanks, Ph.D. and Ross Mangano. The Board of Directors also appointed the individuals to serve as executive officers of the company effective at completion of the Merger and until their successors have been duly elected and qualified or until their earlier resignation or removal: Arthur S. Przybyl as President and Chief Executive Officer, Charlotte C. Arnold as Vice President and Chief Financial Officer, James G. Marken as Vice President, Operations, Robert J. Jamnick as Vice President, Quality and Product Development.

Similar Private Companies By Industry

Company Name Region
Sanofi-Topaz Inc. United States
Unisource, Inc. United States
Pacira Pharmaceuticals, Inc., a California Corporation United States
ActivX Biosciences, Inc. United States
Blackhawk Biosystems, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BioSante Pharmaceuticals, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.